Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2774)
All Articles published online
|
Jun 28, 2006 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E, Tanaka M. Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol 2006; 12(24): 3878-3882 [PMID: 16804974 DOI: 10.3748/wjg.v12.i24.3878] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i24/3878.htm |
| Number | Citing Articles |
| 1 |
Chiara Modica, Dora Tortarolo, Paolo Comoglio, Cristina Basilico, Elisa Vigna. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. International Journal of Molecular Sciences 2018; 19(12): 3920 doi: 10.3390/ijms19123920
|
| 2 |
Zhengchao Zhang, Dong Li, Heng Yun, Jie Tong, Wei Liu, Keqiang Chai, Tongwei Zeng, Zhenghua Gao, Yongqiang Xie. Opportunities and challenges of targeting c-Met in the treatment of digestive tumors. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.923260
|
| 3 |
Dietrich A. Ruess, Kivanc Görgülü, Sonja M. Wörmann, Hana Algül. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs & Aging 2017; 34(5): 331 doi: 10.1007/s40266-017-0453-y
|
| 4 |
Julianna Padavano, Rebecca S. Henkhaus, Hwudaurw Chen, Bethany A. Skovan, Haiyan Cui, Natalia A. Ignatenko. Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer through GTPase Signaling Pathways. Cancer Growth and Metastasis 2015; : CGM.S29407 doi: 10.4137/CGM.S29407
|
| 5 |
Agnieszka A. Rucki, Qian Xiao, Stephen Muth, Jianlin Chen, Xu Che, Jennifer Kleponis, Rajni Sharma, Robert A. Anders, Elizabeth M. Jaffee, Lei Zheng. Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Molecular Cancer Therapeutics 2017; 16(11): 2399 doi: 10.1158/1535-7163.MCT-16-0452
|
| 6 |
Kuttiappan Anitha, Kamal Dua, Dinesh Kumar Chellappan, Gaurav Gupta, Sachin Kumar Singh, Sabapathi Mohana Lakshmi, Shvetank Bhatt. HGF/c-MET: A Potential Target for the Treatment of Various Cancers. Current Enzyme Inhibition 2023; 19(2): 71 doi: 10.2174/1573408019666230227101036
|
| 7 |
Zhi-Yuan Mao, Guang-Qing Zhu, Li Ren, Xiao-Chuan Guo, Dan Su, Li Bai. Prognostic Value of C-met Expression in Cholangiocarcinoma. Technology in Cancer Research & Treatment 2016; 15(2): 227 doi: 10.1177/1533034615578959
|
| 8 |
Wei Huang, Gang Huang, Shuxian An, Jianjun Liu. Molecular imaging of pancreatic ductal adenocarcinoma. VIEW 2023; 4(5) doi: 10.1002/VIW.20230029
|
| 9 |
Dangran Li, Shiting Weng, Kai Zeng, Hanmiao Xu, Wenyueyang Wang, Jinsong Shi, Jinghua Chen, Chen Chen. Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer. Gene 2024; 895: 148007 doi: 10.1016/j.gene.2023.148007
|
| 10 |
Jianliang Zhang, Steven N. Hochwald. Targeting Receptor Tyrosine Kinases in Solid Tumors. Surgical Oncology Clinics of North America 2013; 22(4): 685 doi: 10.1016/j.soc.2013.06.010
|
| 11 |
Loganayaki Periyasamy, Sneha Krishnamoorthy, Bharathi Muruganantham, Ilangovan Ramachandran, Sridhar Muthusami. Cancer Stem Cells and Signaling Pathways. 2024; : 207 doi: 10.1016/B978-0-443-13212-4.00012-X
|
| 12 |
Ming Quan, Peipei Wang, Jiujie Cui, Yong Gao, Keping Xie. The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Molecular Cancer 2013; 12(1) doi: 10.1186/1476-4598-12-159
|
| 13 |
Motahareh Mortazavi, Masoomeh Eskandari, Fatemeh Moosavi, Tahereh Damghani, Mehdi Khoshneviszadeh, Somayeh Pirhadi, Luciano Saso, Najmeh Edraki, Omidreza Firuzi. Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-41283-2
|
| 14 |
Kristen S. Hill, Ivana Gaziova, Lindsay Harrigal, Yvette A. Guerra, Suimin Qiu, Sarita K. Sastry, Thiruvengadam Arumugam, Craig D. Logsdon, Lisa A. Elferink, Surinder K. Batra. Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer. PLoS ONE 2012; 7(7): e40420 doi: 10.1371/journal.pone.0040420
|
| 15 |
Afsane Bahrami, Soodabeh Shahidsales, Majid Khazaei, Majid Ghayour‐Mobarhan, Mina Maftouh, Seyed Mahdi Hassanian, Amir Avan. C‐Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives. Journal of Cellular Physiology 2017; 232(10): 2657 doi: 10.1002/jcp.25794
|
| 16 |
Jacek Śmigielski, Łukasz Piskorz, Renata Talar -Wojnarowska, Ewa Malecka-Panas, Sławomir Jabłoński, Marian Brocki. The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors. World Journal of Surgical Oncology 2013; 11(1) doi: 10.1186/1477-7819-11-137
|
| 17 |
Zobeida Cruz-Monserrate, Suimin Qiu, B Mark Evers, Kathleen L O'Connor. Upregulation and redistribution of integrin α6β4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Modern Pathology 2007; 20(6): 656 doi: 10.1038/modpathol.3800782
|
| 18 |
Yao Liu, Qiaoyan Li, Liwei Zhu. Expression of the Hepatocyte Growth Factor and C-Met in Colon Cancer: Correlation with Clinicopathological Features and Overall Survival. Tumori Journal 2012; 98(1): 105 doi: 10.1177/030089161209800115
|
| 19 |
Katarzyna Gardian, Sława Janczewska, Marek Durlik. Microenvironment Elements Involved in the Development of Pancreatic Cancer Tumor. Gastroenterology Research and Practice 2012; 2012: 1 doi: 10.1155/2012/585674
|
| 20 |
Sadaf Ghanaatgar-Kasbi, Shadi Khorrami, Amir Avan, Seyed A. Aledavoud, Gordon A. Ferns. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Current Pharmaceutical Design 2019; 24(39): 4619 doi: 10.2174/1381612825666190110145855
|
| 21 |
Jun Yu, Kenoki Ohuchida, Kohei Nakata, Kazuhiro Mizumoto, Lin Cui, Hayato Fujita, Hiroshi Yamaguchi, Takuya Egami, Hidehisa Kitada, Masao Tanaka. LIM only 4 is overexpressed in late stage pancreas cancer. Molecular Cancer 2008; 7(1) doi: 10.1186/1476-4598-7-93
|
| 22 |
Hong Hua Yan, Kyung Hee Jung, Mi Kwon Son, Zhenghuan Fang, Soo Jung Kim, Ye-Lim Ryu, Juyoung Kim, Mi-Hyun Kim, Soon-Sun Hong. Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer. Oncotarget 2014; 5(19): 9150 doi: 10.18632/oncotarget.2363
|
| 23 |
Tony C. Y. Pang, Zhihong Xu, Alpha Raj Mekapogu, Srinivasa Pothula, Therese Becker, Susan Corley, Marc R. Wilkins, David Goldstein, Romano Pirola, Jeremy Wilson, Minoti Apte. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. Cancers 2021; 13(11): 2763 doi: 10.3390/cancers13112763
|
| 24 |
Lin Xing, Linlin Lv, Jiaqi Ren, Hao Yu, Xinya Zhao, Xin Kong, Hong Xiang, Xufeng Tao, Deshi Dong. Advances in targeted therapy for pancreatic cancer. Biomedicine & Pharmacotherapy 2023; 168: 115717 doi: 10.1016/j.biopha.2023.115717
|
| 25 |
Kozo Noguchi, Masamitsu Konno, Hidetoshi Eguchi, Koichi Kawamoto, Ryouta Mukai, Naohiro Nishida, Jun Koseki, Hiroshi Wada, Hirofumi Akita, Taroh Satoh, Shigeru Marubashi, Hiroaki Nagano, Yuichiro Doki, Masaki Mori, Hideshi Ishii. c‑Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.8793
|
| 26 |
Penelope Edwards, Byung Woog Kang, Ian Chau. Targeting the Stroma in the Management of Pancreatic Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.691185
|
| 27 |
Yangbing Jin, Zehui Zhang, Siyi Zou, Fanlu Li, Hao Chen, Chenghong Peng, Xiaxing Deng, Chenlei Wen, Baiyong Shen, Qian Zhan. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.634881
|